Quarterly report [Sections 13 or 15(d)]

Revenues from Contracts and Significant Customers (Tables)

v3.26.1
Revenues from Contracts and Significant Customers (Tables)
6 Months Ended
Jun. 30, 2026
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended June 30, 

​

Six Months Ended June 30, 

($ in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Emrosi

​

$

8,074

​

$

2,795

​

$

14,326

​

$

4,865

Qbrexza

​

​

5,114

​

​

6,949

​

​

10,142

​

​

12,110

Accutane

​

​

3,358

​

​

3,395

​

​

6,672

​

​

7,050

Foam franchise products (Amzeeq & Zilxi)

​

​

941

​

​

1,135

​

​

1,991

​

​

2,661

Other / legacy product revenue

​

​

232

​

​

735

​

​

509

​

​

1,462

Eurax

​

​

120

​

​

—

​

​

120

​

​

—

Other revenue

​

​

879

​

​

1,404

​

​

996

​

 

1,404

Total net revenue

​

$

18,718

​

$

16,413

​

$

34,756

​

$

29,552